ELAN

Elanco is a pure-play animal-health company with a solid product gross margin of 55.0% and renewed top-line momentum — FY2025 revenue grew 6.2% to $4.71B, the best growth in the five-year record after several flat years. Yet the company swung back to a GAAP net loss of -$232M (EPS -$0.47) from a +$338M profit in FY2024, leaving net margin at -4.9% and ROE at -3.5%. The five-year history is volatile: losses of -$483M, -$78M and -$1.23B (FY2021-FY2023), a single profitable year, and now another loss. Much of this reflects the heavy intangible amortization from its Bayer-era acquisition — depreciation and amortization of $680M dwarfs the reported loss, so cash earnings are meaningfully better than GAAP.

The cash and balance-sheet picture supports a constructive but cautious read. Operating cash flow was positive at $560M (+3.5%), though capex nearly doubled (+87.8% to $276M), compressing free cash flow. Management is deleveraging — long-term debt fell 12.9% to $3.76B — and liabilities/equity is a manageable 1.04x with $545M of cash (+16.5%). The accumulated deficit of -$2.18B and absence of buybacks/dividends mean cash is being directed to debt reduction and reinvestment (R&D up 7.0% to $368M).